Quest for the right Drug
אסאקול 400 ASACOL 400 (MESALAZINE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליות עם ציפוי אנטרי : TABLETS ENTERIC COATED
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects a) Summary of the safety profile Organ specific adverse drug reactions affecting the heart, lungs, liver, kidneys, pancreas, skin and subcutaneous tissue have been reported. Treatment must be stopped immediately if acute symptoms of intolerance occur such as abdominal cramps, acute abdominal pain, fever, severe headache and rash, see section 4.4. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment (see section 4.4). b) Tabulated summary of adverse reactions Undesirable effects relevant for the labeling reported from eight (8) double-blind and five (5) open clinical studies with 739 patients treated with Asacol 400 mg enteric coated tablets are listed below. Common Uncommon Rare Very rare Frequency not System Organ (≥ 1/100 (≥ 1/1,000 (≥ 1/10,000 to < (< 1/10,000) known Class to < 1/10) to < 1/100) 1/1,000) Blood and eosinophilia altered blood lymphatic (as part of counts (aplastic system an allergic anemia, disorders reaction) agranulocytosis, pancytopenia, neutropenia, leucopenia, thrombocytopenia) Immune system hypersensitivity disorders reactions such as allergic exanthema, drug fever, lupus erythematosus syndrome, pancolitis Nervous system paresthesia headache, peripheral disorders dizziness neuropathy Cardiac myocarditis, disorders pericarditis Respiratory, allergic and fibrotic pleurisy thoracic and lung reactions mediastinal (including disorders dyspnoea, cough bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis), interstitial pneumonia, eosinophilic pneumonia, lung disorder Gastrointestinal dyspepsia abdominal pain, acute pancreatitis disorders diarrhoea, flatulence, nausea, vomiting Common Uncommon Rare Very rare Frequency not System Organ (≥ 1/100 (≥ 1/1,000 (≥ 1/10,000 to < (< 1/10,000) known Class to < 1/10) to < 1/100) 1/1,000) Hepato-biliary changes in liver disorders function parameters (increase in transaminases and cholestasis parameters), hepatitis, cholestatic hepatitis Skin and rash urticaria, photosensitivity* alopecia Stevens- subcutaneous pruritus Johnson tissue disorders syndrome (SJS), toxic epidermal necrolysis (TEN) Musculoskeletal, myalgia, arthralgia lupus-like connective syndrome with tissue and bone pericarditis and disorders pleuropericarditis as prominent symptoms as well as rash and arthralgia Renal and Impairment of renal Nephrolithiasis** urinary function including disorders acute and chronic interstitial nephritis, renal insufficiency, nephrotic syndrome and renal failure which may be reversible on early withdrawal Reproductive oligospermia system and (reversible) breast disorders General pyrexia, intolerance to disorders and chest pain, mesalazine with administration C-reactive site conditions protein increased and/or exacerbation of symptoms of underlying disease Common Uncommon Rare Very rare Frequency not System Organ (≥ 1/100 (≥ 1/1,000 (≥ 1/10,000 to < (< 1/10,000) known Class to < 1/10) to < 1/100) 1/1,000) Investigations blood creatinine increased, weight decreased, creatinine clearance decreased, amylase increased, red blood cell sedimentation rate increased, lipase increased, BUN increased *see section c) **see section 4.4 for further information c) Description of selected adverse reactions An unknown number of the above mentioned undesirable effects are probably associated to the underlying IBD rather than Asacol/mesalazine medication. This holds true especially for gastrointestinal undesirable effects, arthralgia, and alopecia. To avoid blood dyscrasia resulting from developing bone marrow depression patients should be monitored with care, see section 4.4. Under co-administration of mesalazine with immunosuppressive drugs, such as azathioprine or 6-MP or thioguanine, life-threatening infection can occur, see section 4.5. Photosensitivity More severe reactions are reported in patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema. d) Paediatric population There is only limited safety experience with the use of Asacol tablets in the paediatric population. It is expected that the target organs of possible adverse reactions in the paediatric population are the same as for adults (heart, lungs, liver, kidneys, pancreas, skin and subcutaneous tissue). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il/
שימוש לפי פנקס קופ''ח כללית 1994
Maintenance of remission in ulcerative colitis, acute episodes of Crohn's disease
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף